Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AVITA Medical (RCEL) Revenue (2018 - 2025)

AVITA Medical's Revenue history spans 8 years, with the latest figure at $92.0 million for Q4 2025.

  • For Q4 2025, Revenue rose 399.84% year-over-year to $92.0 million; the TTM value through Dec 2025 reached $145.6 million, up 126.71%, while the annual FY2025 figure was $71.6 million, 11.45% up from the prior year.
  • Revenue reached $92.0 million in Q4 2025 per RCEL's latest filing, up from $16.9 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $92.0 million in Q4 2025 to a low of $7.0 million in Q3 2021.
  • Average Revenue over 5 years is $16.9 million, with a median of $11.8 million recorded in 2023.
  • Peak YoY movement for Revenue: decreased 19.11% in 2022, then soared 399.84% in 2025.
  • A 5-year view of Revenue shows it stood at $7.0 million in 2021, then skyrocketed by 34.69% to $9.5 million in 2022, then skyrocketed by 50.13% to $14.2 million in 2023, then increased by 29.67% to $18.4 million in 2024, then skyrocketed by 399.84% to $92.0 million in 2025.
  • Per Business Quant, the three most recent readings for RCEL's Revenue are $92.0 million (Q4 2025), $16.9 million (Q3 2025), and $18.2 million (Q2 2025).